Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma
Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma
复制标题
DOI：
10.1200/jco.2007.12.1087
复制
发表时间：
2007-10-20
影响因子：
45.3
通讯作者：
Kwon, Eugene D.
中科院分区：
文献类型：
--
作者：
Leibovich, Bradley C.;Sheinin, Yuri;Kwon, Eugene D.
目的 据报道，碳酸酐酶IX（CAIX）的表达是预后的独立预测因子，并且作为透明细胞肾细胞癌（ccRCC）患者的治疗靶点正在被研究。我们试图通过一大群有长期随访的ccRCC患者来验证CAIX表达在预后判断上的实用性。
患者和方法 我们确定了730例在1990年到1999年间接受手术治疗的单侧、散发性ccRCC患者。使用抗CAIX单克隆抗体（克隆M75），并对肿瘤标本的表达水平进行盲法评分。使用Cox比例风险回归模型评估CAIX表达与肾细胞癌死亡的相关性。
结果 有241例肾细胞癌死亡病例，仍在观察的患者中位随访时间为9.4年。708份（97.0%）标本表达CAIX；163个肿瘤（22.3%）呈现低表达（……此处原文不完整）
Purpose Expression of carbonic anhydrase IX (CAIX) has been reported to be an independent predictor of outcome and is being investigated as a therapeutic target for patients with clear cell renal cell carcinoma (ccRCC). We attempted to validate the prognostic utility of CAIX expression using a large cohort of ccRCC patients with long-term follow-up.Patients and Methods We identified 730 patients with unilateral, sporadic ccRCC treated surgically between 1990 and 1999. Anti-CAIX monoclonal antibody (clone M75) was used, and tumor specimens were blindly scored for expression levels. Associations of CAIX expression with RCC death were evaluated using Cox proportional hazards regression models.Results There were 241 RCC deaths and a median of 9.4 years of follow-up for patients still under observation. CAIX was expressed in 708 (97.0%) of the specimens; 163 tumors (22.3%) exhibited low (